MH-BactoProtech is a technology based on the patented live (probiotic) or inactivated (paraprobiotic) bacterial strains of Lactobacillus helveticus MIMLh5.
The probiotic approach represents an alternative strategy in the prevention and treatment of infectious diseases, not only at the intestinal level but also at other sites of the body where the microbiota plays a role in the maintenance of physiological homeostasis.
Metis Healthcare has the exclusive license for MIMLh5 to prevent Streptococcus pyogenes infections at the pharyngeal level (pharyngitis).
MH-BactoProtech, based on Lactobacillus helveticus MIMLH5, was studied in its action of competition with pathogens, reduction of inflammation, immunomodulation activity, and reduction of symptoms of allergic reactions through the restoring of the Th1/Th2 balance5
Our products based on MH-BactoProtech: